Status:
COMPLETED
Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT
Lead Sponsor:
Shehnoor Azhar
Conditions:
COVID 19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the effectiveness of Hydroxychloroquine Sulfate (200 mg orally 8hr thrice a day for 5 days) vs oseltamivir (75 mg orally twice a day for 5 days) vs Azithromycin (500 mg orally daily on day...
Detailed Description
A scientific taskforce notified by the Ministry of Science and Technology of the Government of Pakistan will oversee a comprehensive cohort study. Within this cohort, a multicenter, adaptive, randomiz...
Eligibility Criteria
Inclusion
- Confirmed SARS-CoV-2 (COVID-19) infection by a positive test result
- Either gender
- Symptomatic for example fever, dry Cough, difficulty to breathe
Exclusion
- Confirmed absence of SARS-CoV-2 (COVID-19) infection by a negative test result
- Have chronic conditions such as heart disease, liver and kidney failure
- Pregnant or currently lactating
- Immunocompromise and/or systemic disease(s)
- On other antiviral drugs
- History of allergy to any of the drugs to be administered in this study
Key Trial Info
Start Date :
April 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 22 2020
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT04338698
Start Date
April 22 2020
End Date
November 22 2020
Last Update
February 10 2022
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Gujranwala Medical College
Chak Two Hundred Fourteen, Pakistan
2
Nawaz Sharif Medical College
Dhok Gujra, Pakistan
3
Faislabad Medical University
Faisalābad, Pakistan
4
Szabmu-Pims
Islamabad, Pakistan